Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.56 |
| ▸ | SELL | P14151 | 2/20 | 0.56 |
| ▸ | SELE | P16581 | 4/20 | 0.54 |
| ▸ | MAG | P20916 | 6/20 | 0.53 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454799 | 0.91 | SELP (0.62) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL17903220 | 0.89 | SELP (0.64) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL18211294 | 0.89 | SELP (0.64) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL28100889 | 0.89 | MAG (0.59) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL29709547 | 0.89 | SELP (0.63) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL29358356 | 0.88 | MAG (0.64) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL29790139 | 0.87 | SIGLEC7 (0.63) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL29809799 | 0.87 | SIGLEC7 (0.63) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL31010809 | 0.85 | SELP (0.71) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL21318923 | 0.85 | MAG (0.62) | SELPSELLMAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260086095-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY ARCTIC PARTNERS AB (FI) | 2026-03-26 | — | — | US | disclosed |
| EP-4581365-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY Arctic Partners AB (FI) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047283-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY ARCTIC PARTNERS AB (FI) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260086095-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | LGALS9, KLK3, SIGLEC9 | SELP 108/4885SELL 163/4885SELE 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.